A variety of novel 2-butyl-3-substituted quinazolin-4-(3H)-ones have been synthesized by reacting (2-butyl-4-oxo-3H-quinazolin-3-yl)dithiocarbamic acid methyl ester with a variety of amines; the starting material dithiocarbamate was synthesized from anthranilic acid. The title compounds were investigated for analgesic, anti-inflammatory and antibacterial activities. While the test compounds exhibited significant activity, compounds A1, A2, A3 and A4 showed more potent analgesic activity and compound A4 showed more potent anti-inflammatory activity than the reference diclofenac sodium.
Bacterial infections often produce pain and inflammation. In normal practice, two groups of agents (chemotherapeutic, analgesic and anti-inflammatory) are prescribed simultaneously. Compounds possessing all three activities are not common. Quinazolines and condensed quinazolines exhibit potent antimicrobial 1) and central nervous system (CNS) activities like analgesic, 2) anti-inflammatory 3) and anticonvulsant 4) activities. In view of these facts and to develop our earlier reported 2-phenyl-3-substituted quinazolines, 5) 2,3-disubstituted quinazolines, 6) 2-methyl-3-substituted quinazolin-4-(3H)-ones 7) and 2-methylthio-3-substituted quinazolin-4-(3H)-ones 8) that exhibited good analgesic and anti-inflammatory activities, in the present study we aimed to synthesize some 2-butyl-3-substituted quinazolin-4(3H)-ones. The title compounds were synthesized by nucleophilic substitution of (2-butyl-4-oxo-3H-quinazolin-3-yl)dithiocarbamic acid methyl ester with different amines. The (2-butyl-4-oxo-3H-quinazolin-3-yl)dithiocarbamic acid methyl ester was synthesized by reacting the amino group of 3-amino-2-butylquinazoline with carbondisulphide and dimethyl sulphate. The 3-amino-2-butylquinazoline was synthesized from anthranilic acid (Chart 1). Spectral data (IR, NMR and mass spectra) confirmed the structures of the synthesized compounds, and their purity was ascertained by microanalysis ( Table 1) . The synthesized compounds were tested for their analgesic, anti-inflammatory and antibacterial activities.
CHEMISTRY
Melting points were determined in open capillary tubes on a Thomas Hoover apparatus and are uncorrected. IR spectra were recorded in KBr on a Perkin Elmer-841 grating spectrometer (cm Ϫ1 ), mass spectra on a Varian Atlas CH-7 mass spectrometer at 70 eV and NMR spectra on a Varian A-60 or EM-360 spectrometer, using tetramethylsilane as internal standard. Elemental analyses were performed on Carlo erba 1108.
Synthesis of 3-Amino-2-(n-butyl)-3H-quinazolin-4-one A mixture of anthranilic acid (0.01 mol) and pentanoic anhydride (0.05 mol) was refluxed under anhydrous conditions for 3 h. Excess liquid was distilled off under reduced pressure and the reaction mixture was cooled to room temperature. The solid obtained was dissolved in pyridine (50 ml), hydrazine hydrate (0.02 mol) was added and refluxed for 4 h, cooled to room temperature and poured into a mixture of ice (50 g) and concentrated hydrochloric acid (50 ml). The reaction mixture was kept overnight, the solid separated was filtered, washed well with water, dried and recrystallized from ethanol. Yieldϭ53%, mp 110-112°C; IR (KBr) 
Synthesis of 1-Methyl-3-(2-(n-butyl)-4-oxo-3H-quinazolin-3-yl)thiourea (A1)
A mixture of (2-butyl-4-oxo-3H-quinazolin-3-yl)dithiocarbamic acid methyl ester 3.07 g (0.01 mol) and methylamine 0.62 g (0.02 mol) in N,N-Dimethyl formamide (20 ml) was refluxed for 23 h, cooled and poured into ice water, the solid obtained was filtered, dried and recrystallized from ethanol. Yieldϭ69%, mp 155-156°C, IR (KBr) cm 
PHARMACOLOGY
The synthesized compounds were evaluated for analgesic, anti-inflammatory and antimicrobial activities. Student t-test was performed to ascertain the significance of all the exhibited activities. The test compounds and the standard drugs were administered in the form of a suspension (1% carboxyl methyl cellulose as vehicle) by the same route of administration. Each group consisted of six animals.
Animals The animals were procured from the National Biological Center, Madurai, India, and were maintained in colony cages at 25Ϯ2°C, relative humidity of 45-55%, under a 12 h light and dark cycle; they were fed standard animal feed. All the animals were acclimatized for a week before use.
Analgesic Activity 9, 10) Test for analgesic activity was performed by tail-flick technique using Wistar albino mice (25-35 g) of either sex selected by random sampling technique. Diclofenac sodium at a dose level of 10 mg/kg and 20 mg/kg was administered orally as reference drug for comparison. The test compounds at two dose levels (10, 20 mg/kg) were administered orally. The reaction time was recorded at 30 min, 1, 2 and 3 h after the treatment, and cut-off time was 10 s. The percent analgesic activity (PAA) was calculated by the following formula, where T 1 is the reaction time (s) before treatment, and T 2 is the reaction time (s) after treatment.
Anti-inflammatory Activity Anti-inflammatory activity was evaluated by carrageenan-induced paw oedema test in rats.
11) Diclofenac sodium 10, 20 mg/kg was administered as a standard drug for comparison. The test compounds were administered at two dose levels (10, 20 mg/kg). The paw volumes were measured using the mercury displacement technique with the help of a plethysmograph immediately before and 30 min, 1, 2 and 3 h after carrageenan injection. The per- where x is the mean paw volume of rats before the administration of carrageenan and test compounds or reference compound (test group), a is the mean paw volume of rats after the administration of carrageenan in the test group (drug treated), b is the mean paw volume of rats after the administration of carrageenan in the control group, y is the mean paw volume of rats before the administration of carrageenan in the control group. Antibacterial Activity Evaluation of antibacterial activity by agar dilution method.
12) The standard strains were procured from the American Type Culture Collection (ATCC), Rockville, U.S.A., and the pathological strains were procured from the Department of Microbiology, Madurai Medical College and Research Institute, Madurai, India. The antibacterial activity of the synthesized compounds was screened against the following bacterial strains: Proteus vulgaris ATCC 9484, Salmonella typhimurium ATCC 33068, Klbsilla pneumoniae ATCC 13883, Edwersiella tarda, Pseudomonas aeruginosa ATCC 2853, Bacillus subtilis ATCC 6051, and Salmonella paratyphi. All bacteria were grown on Muller-Hinton Agar (Hi-media) plates (37°C, 24 h) and the minimum inhibitory concentration (MIC) was considered to be the lowest concentration that completely inhibited the growth on agar plates, disregarding a single colony or faint haze caused by the inoculums. The MIC of the test compounds was compared with the reference drug norfloxacin.
RESULTS AND DISCUSSION
The results of analgesic activity indicate that all the test compounds exhibited significant activity (Table 2) . Compound A1 with methyl substitution showed good activity; with increased lipophilicity (dimethyl group), compound A2 showed an increase in activity. Further increase in lipophilicity (diethyl group) A3 led to even greater activity. Substitution with alicyclic amines (pyrolidine) A4 showed little more increase in activity and placement of alicyclic amines with additional heteroatoms A5, A6 led to a decrease in activity. Aromatic substitution A7-A10 showed still lower activity. The compounds with aliphatic substitution (A1-A4) showed better activity. Compound A4 was found to be the most active analgesic agent and was more potent than diclofenac sodium and our earlier reported 2,3-disubstituted quinazolin-4(3H)-ones.
The anti-inflammatory activity data (Table 3) indicated that all the test compounds protected rats from carrageenaninduced inflammation and are more potent than our earlier reported 2,3-disubtituted quinazolin-4(3H)-ones. Compound A4 showed more antiinflammatory activity than diclofenac sodium.
The results of antibacterial activity (Table 4) indicate that all the test compounds exhibited moderate activity against the tested bacteria. Compound A7 showed good activity against E. tarda, S. typhimurium and P. vulgaris; the compound A8 exhibited good activity against E. tarda and S. typhimurium, while compound A9 exhibited good activity against S. paratyphi, S. typhimurium and P. vulgaris.
In our earlier studies we observed that the presence of alkyl groups exhibited more analgesic and anit-inflammatory activities over aryl groups at the N-3 position. Hence in the the C-2 position also we made a substitution in such a way as to increase lipophilicity of the molecule. The placement of such a group enhanced the analgesic and anti-inflammatory activities. To compare the increase in activity we have taken the average of all the readings of reaction time noted for each compound for each pharmacological activity. The most ac- tive compound of the C-2 phenyl series showed 43% analgesic and 36% anti-inflammatory activity, whereas the C-2 methyl series lead molecule showed 50% analgesic and 44% anti-inflammatory activity. The present series of title compounds was obtained with further increase of lipophilicity by introducing butyl group at C-2. The lead compound of the present series showed 60% analgesic and 43% anti-inflammatory activity. The increase in analgesic and anti-inflammatory activities may be due to the fact that the present series has a highly lipophilic group (butyl) that enhanced these activities. There was only slight increase in antibacterial activity, however. Hence further structural modification is planned to increase not only the analgesic and anti-inflammatory activities also the antibacterial activity. Vol. 28, No. 6 
